Carlo Rinaldi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6370980/publications.pdf

Version: 2024-02-01

39 papers	1,750 citations	331259 21 h-index	301761 39 g-index
41 all docs	41 docs citations	41 times ranked	3086 citing authors

#	Article	IF	Citations
1	AR cooperates with SMAD4 to maintain skeletal muscle homeostasis. Acta Neuropathologica, 2022, 143, 713-731.	3.9	6
2	MicroRNA-298 reduces levels of human amyloid-Î² precursor protein (APP), Î²-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties. Molecular Psychiatry, 2021, 26, 5636-5657.	4.1	61
3	Targeting the 5â€² untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy. Molecular Therapy - Nucleic Acids, 2021, 23, 731-742.	2.3	3
4	Dystrophin involvement in peripheral circadian SRF signalling. Life Science Alliance, 2021, 4, e202101014.	1.3	1
5	Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity. Science Advances, 2021, 7, .	4.7	20
6	Variants in ATP6V0A1 cause progressive myoclonus epilepsy and developmental and epileptic encephalopathy. Brain Communications, 2021, 3, fcab245.	1.5	10
7	Plasma pNfH levels differentiate SBMA from ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 215-217.	0.9	11
8	Polyglutamine-Expanded Androgen Receptor Alteration of Skeletal Muscle Homeostasis and Myonuclear Aggregation Are Affected by Sex, Age and Muscle Metabolism. Cells, 2020, 9, 325.	1.8	21
9	Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology, 2019, 92, e1205-e1211.	1.5	41
10	Beyond motor neurons: expanding the clinical spectrum in Kennedyâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 808-812.	0.9	48
11	From gene to therapy in spinal and bulbar muscular atrophy: Are we there yet?. Molecular and Cellular Endocrinology, 2018, 465, 113-121.	1.6	18
12	Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nature Reviews Neurology, 2018, 14, 9-21.	4.9	515
13	Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents. Journal of Visualized Experiments, 2018, , .	0.2	7
14	The Multiple Faces of Spinocerebellar Ataxia type 2. Annals of Clinical and Translational Neurology, 2017, 4, 687-695.	1.7	24
15	Proteostasis and Diseases of the Motor Unit. Frontiers in Molecular Neuroscience, 2016, 9, 164.	1.4	4
16	MiR-298 Counteracts Mutant Androgen Receptor Toxicity in Spinal and Bulbar Muscular Atrophy. Molecular Therapy, 2016, 24, 937-945.	3.7	29
17	A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy. Human Molecular Genetics, 2016, 25, 1979-1989.	1.4	55
18	Targeted Molecular Therapies for SBMA. Journal of Molecular Neuroscience, 2016, 58, 335-342.	1.1	10

#	Article	IF	Citations
19	The Role of the Protein Quality Control System in SBMA. Journal of Molecular Neuroscience, 2016, 58, 348-364.	1.1	32
20	Mutation inCPT1CAssociated With Pure Autosomal Dominant Spastic Paraplegia. JAMA Neurology, 2015, 72, 561.	4.5	64
21	Early onset and novel features in a spinal and bulbar muscular atrophy patient with a 68 CAG repeat. Neuromuscular Disorders, 2014, 24, 978-981.	0.3	37
22	Spinal and bulbar muscular atrophy: pathogenesis and clinical management. Oral Diseases, 2014, 20, 6-9.	1.5	41
23	Muscle Matters in Kennedyâ€™s Disease. Neuron, 2014, 82, 251-253.	3.8	13
24	Ataxia with oculomotor apraxia type 2 fibroblasts exhibit increased susceptibility to oxidative DNA damage. Journal of Clinical Neuroscience, 2014, 21, 1627-1631.	0.8	15
25	Stem cell-derived motor neurons from spinal and bulbar muscular atrophy patients. Neurobiology of Disease, 2014, 70, 12-20.	2.1	49
26	Hereditary Spastic Paraplegia Type 43 (SPG43) is Caused by Mutation inC19orf12. Human Mutation, 2013, 34, 1357-1360.	1.1	79
27	Insulin Sensitivity and Early-Phase Insulin Secretion in Normoglycemic Huntington's Disease Patients. Journal of Huntington's Disease, 2013, 2, 501-507.	0.9	18
28	A candidate gene for autoimmune myasthenia gravis. Neurology, 2012, 79, 342-347.	1.5	21
29	Predictors of Survival in a Huntington's Disease Population from Southern Italy. Canadian Journal of Neurological Sciences, 2012, 39, 48-51.	0.3	41
30	Cowchock Syndrome Is Associated with a Mutation in Apoptosis-Inducing Factor. American Journal of Human Genetics, 2012, 91, 1095-1102.	2.6	134
31	Insulinlike Growth Factor (IGF)-1 Administration Ameliorates Disease Manifestations in a Mouse Model of Spinal and Bulbar Muscular Atrophy. Molecular Medicine, 2012, 18, 1261-1268.	1.9	56
32	A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. Journal of Neurology, 2012, 259, 132-138.	1.8	47
33	Growth hormone response to arginine test differentiates between two subgroups of Huntington's disease patients. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 543-547.	0.9	10
34	Benign hereditary chorea: Clinical and neuroimaging features in an Italian family. Movement Disorders, 2010, 25, 1491-1495.	2.2	32
35	Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsingâ€” remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Multiple Sclerosis Journal, 2010, 16, 450-454.	1.4	79
36	Course and outcome of a voltage-gated potassium channel antibody negative Morvanâ€™s syndrome. Neurological Sciences, 2009, 30, 237-239.	0.9	14

#	Article	IF	Citations
37	Two novel CYP7B1 mutations in Italian families with SPG5: a clinical and genetic study. Journal of Neurology, 2009, 256, 1252-1257.	1.8	39
38	Suppression of myoclonus in SCA2 by piracetam. Movement Disorders, 2006, 21, 116-118.	2.2	14
39	The R495W mutation in SPG3A causes spastic paraplegia associated with axonal neuropathy. Journal of Neurology, 2005, 252, 901-903.	1.8	31